CLINICAL_TRIALS
trial_result
· 2013-06-26
Clinical Trial Update: Ecteinascidin 743 in Treating Patients With Unresectable Advanced or Metastatic Soft Tissue Sarcoma [Phase 2]
Summary
A Phase 2 trial evaluating ecteinascidin 743 in patients with unresectable advanced or metastatic soft tissue sarcoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Sarcoma | Phase 2 | Status: COMPLETED